论文部分内容阅读
目的:研究通心络胶囊联合阿托伐他汀钙片对冠心病患者血脂及炎症因子影响的药理分析。方法:选取在我院2014年6月—2015年6月接受治疗的冠心病患者114例。按照随机分组原则将患者分为治疗组58例和对照组56例。对照组在冠心病基础治疗上给予口服阿托伐他汀钙片,而治疗组为阿托伐他汀钙片联合通心络胶囊治疗,治疗疗程为2个月。观察分析两组治疗前后血脂水平及炎症因子的变化。结果:两组患者接受不同治疗前,发现两组在总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、肿瘤坏死因子-α(TNF-α)、白细胞介素6(IL-6)及超敏C-反应蛋白(hs-CRP)各指标上,差异无统计学意义(P>0.05),而在接受治疗后,发现两组的TC、TG、LDL-C较治疗前都有明显下降,HDL-C则都明显提高,差异均有统计学意义(P<0.05)。而对比两组间治疗后的各项指标,发现治疗组TC、TG、LDL-C水平又明显低于对照组,HDL-C水平也明显高于对照组,且差异均有统计学意义(P<0.05)。同时发现在接受治疗后,两组的TNF-α、IL-6、hs-CRP较治疗前都有明显下降,差异均有统计学意义(P<0.05)。而对比两组间治疗后的各项指标,发现治疗组TNF-α、IL-6、hs-CRP水平又明显低于对照组,差异具有统计学意义(P<0.05)。结论:采用通心络胶囊联合阿托伐他汀钙片治疗冠心病患者,可明显降低血脂和炎症因子水平,降低发病危险,提高治疗质量,值得临床推广。
Objective: To study the pharmacological effects of Tongxinluo capsule combined with atorvastatin calcium on blood lipid and inflammatory factors in patients with coronary heart disease. Methods: A total of 114 patients with coronary heart disease who were treated in our hospital from June 2014 to June 2015 were selected. Patients were divided into treatment group (58 cases) and control group (56 cases) according to the principle of randomization. The control group was given oral atorvastatin calcium tablets in the treatment of coronary heart disease, while the treatment group was treated with atorvastatin calcium tablets and Tongxinluo Capsules. The treatment course was 2 months. Observe and analyze the changes of blood lipid level and inflammatory factors in two groups before and after treatment. Results: Before the two groups of patients received different treatment, two groups were found to have significant differences in the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL- There was no significant difference between each index of TNF-α, IL-6 and hs-CRP (P> 0.05) After treatment, the levels of TC, TG and LDL-C in both groups were significantly lower than those before treatment, while the levels of HDL-C were significantly increased (all P <0.05). Comparing the indexes after treatment, we found that the levels of TC, TG and LDL-C in the treatment group were significantly lower than those in the control group, and the levels of HDL-C were also significantly higher than those in the control group (P <0.05). Also found that after treatment, the two groups of TNF-α, IL-6, hs-CRP than before treatment were significantly decreased, the differences were statistically significant (P <0.05). Comparing the two indexes after treatment, we found that the levels of TNF-α, IL-6 and hs-CRP in the treatment group were significantly lower than those in the control group, the difference was statistically significant (P <0.05). Conclusion: Tongxinluo capsule combined with atorvastatin calcium tablets in patients with coronary heart disease can significantly reduce the level of blood lipids and inflammatory cytokines, reduce the risk of disease and improve the quality of treatment, it is worth clinical promotion.